View original post here:
CorMedix Inc. Supports CMS Policy Updates Regarding Access to Innovative Drug Products
Related Post
- Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) - November 26th, 2024
- 35Pharma Closes Series C Financing to Advance Clinical Pipeline of Activin Inhibitors for Pulmonary Hypertension, Cardiometabolic Disease and Obesity - November 26th, 2024
- Helio Genomics Presented CLiMB Trial Data Evaluating HelioLiver for Detecting Early-Stage HCC and Methylation Model Score for Assessing Prognosis at... - November 26th, 2024
- Medigene AG Announces Refocus of Corporate Strategy and Organizational Realignment - November 26th, 2024
- Renexxion Ireland Ltd. Announces Issuance of Fifth New U.S. Patent Covering Novel Crystal Isoform of Naronapride - November 26th, 2024
- Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society... - November 26th, 2024
- Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference - November 26th, 2024
- Aligos Therapeutics to Present at Investor Conferences in December - November 26th, 2024
- Cabaletta Bio to Participate in Upcoming Investor Conferences in December - November 26th, 2024
- Tevogen Bio Prepares Organizational Readiness to Support Company’s Growth Strategy - November 26th, 2024
- Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome - November 26th, 2024
- Intelligent Bio Solutions Achieves 94.1% Accuracy in Method Comparison Study, Following Positive PK Study Results - November 26th, 2024
- Gelteq Announces 400,000 Units Enter into Production in November 2024 - November 26th, 2024
- Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders - November 26th, 2024
- Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer... - November 26th, 2024
- Wave Life Sciences to Present at Upcoming Investor Conferences - November 26th, 2024
- Stem Cells, Superstars, And Supershow: WWE Superstar Elias Set to Face Off at WrestleCade SuperShow 2024 This Weekend - November 26th, 2024
- Umoja Biopharma to Present at the 7th Annual Evercore ISI HealthCONx Conference - November 26th, 2024
- Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA - November 26th, 2024
- Bluejay Therapeutics Announces Expansion of Leadership Team and Board of Directors - November 25th, 2024
- GRI Bio Showcases GRI-0621’s Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF) - November 25th, 2024
- Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to... - November 25th, 2024
- Vilya Announces Exclusive License Agreement of RFdiffusion-based Generative Model from the University of Washington for the Design of Macrocyclic... - November 25th, 2024
- Chromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program Updates - November 25th, 2024
- Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting - November 25th, 2024
- AscellaHealth Ranked Number 154 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™ - November 25th, 2024
- Bio Usawa and Rwandan Government Sign a Memorandum of Understanding to Manufacture Affordable Biologics in Africa - November 25th, 2024
- Inventiva reports 2024 Third Quarter Financial Information¹ - November 25th, 2024
- Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential... - November 25th, 2024
- Korro to Participate in Upcoming Investor Conferences - November 25th, 2024
- Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval... - November 25th, 2024
- Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related... - November 25th, 2024
- Organogenesis Expands Manufacturing Capacity to Support Future Growth - November 25th, 2024
- CAMP4 Reports Third Quarter 2024 Financial Results - November 22nd, 2024
- Seer Ranked Number 57 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™ - November 22nd, 2024
- Lifecore Biomedical Hosts Virtual Investor Day - November 22nd, 2024
- BioAge Labs to Present at Upcoming Investor Conferences - November 22nd, 2024
- Kane Biotech to Release Third Quarter 2024 Financial Results on November 28, 2024 - November 22nd, 2024
- High Haven Celebrates "Danksgiving" Cannabis Event with Green Wednesday and Holiday Deals Across Illinois Locations - November 22nd, 2024
- HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan - November 22nd, 2024
- BioAdaptives, Inc. Announces 5 Unique Products Ready for Phased Entry Into the Nutritional Marketplace - November 22nd, 2024
- Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - November 22nd, 2024
- Scilex Holding Company Announces Receipt of Notice from Nasdaq - November 22nd, 2024
- Orion Research Foundation grants EUR 1,109,000 for research in 2025 - November 22nd, 2024
- NewGenIvf Receives Nasdaq Delisting Notice and Plans to Submit Appeal, Announces Strategic Path Forward to Regain Compliance - November 22nd, 2024
- Eyenovia Provides Update on Restructuring Efforts - November 22nd, 2024
- Seres Therapeutics to Participate in Piper Sandler Healthcare Conference - November 22nd, 2024
- Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and... - November 22nd, 2024
- Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular... - November 22nd, 2024
- Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA - November 22nd, 2024
- Result of General Meeting - November 22nd, 2024
- Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note - November 22nd, 2024
- Raw Garden Unveils Unprecedented “Thankful For You” Deals for Green Wednesday, Black Friday, and Cyber Monday - November 22nd, 2024
- MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders - November 20th, 2024
- Biopharma Leaders of Color (BLOC) Announces Board of Directors and Establishes Executive Council to Expand and Enhance Offerings - November 20th, 2024
- Invizyne Technologies Selected for $2 Million Project to Advance Sustainable Aviation Fuel Capabilities - November 20th, 2024
- Synata Bio’s Sylonto Project Awarded $4.5 Million NDRC Grant - November 20th, 2024
- Kaida BioPharma Announces Formation of Scientific Advisory Board to Support Development of KAD101 for Ovarian Cancer - November 20th, 2024
- Orion and Alligator Bioscience amend their agreement concerning two bispecific antibodies - November 20th, 2024
- Conquer the New MJBizCon Expo Floor, One Pavilion at a Time - November 20th, 2024
- Helio Genomics to Host Virtual KOL Event to Discuss Recent CLiMB Trial Data and Methylation Model Score in Patients with Hepatocellular Carcinoma... - November 20th, 2024
- TELA Bio to Participate in Piper Sandler’s 36th Annual Healthcare Conference - November 20th, 2024
- Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024 - November 20th, 2024
- Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation - November 20th, 2024
- Regen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXellerate™ - November 20th, 2024
- Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference - November 20th, 2024
- Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors - November 20th, 2024
- Abivax Establishes an At-the-Market (ATM) Program on Nasdaq - November 20th, 2024
- Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program - November 20th, 2024
- Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance... - November 20th, 2024
- argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies - November 20th, 2024
- Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALS - November 20th, 2024
- HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee - November 20th, 2024
- MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia - November 18th, 2024
- Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer - November 18th, 2024
- Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on... - November 18th, 2024
- EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome - November 18th, 2024
- genXtraits Inc. licenses Fulcrum™ toolkit from Pairwise to enable its technology platform for generation of high-value enhanced crops with dominant... - November 18th, 2024
- Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline - November 18th, 2024
- Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning... - November 18th, 2024
Recent Comments